Sygnature Discovery moves U.S. office to life science mecca Kendall Square

Kendall Square
Kendall Square (Tim Pierce/Public domain)

Drug discovery company Sygnature Discovery is moving its U.S. office to Kendall Square, the heart of the Cambridge–Boston biotech hub in Massachusetts.

The new office, at 245 First Street in Cambridge, is “only a small move geographically,” as the CRO admits (only down the road from the old location near Harvard Square), but Sygnature argues "it is significant” given there are more than 100 life science companies within a mile of the new office.

It hopes that in moving closer to what is perceived to be the nucleus of U.S. biopharma it will be able to rub shoulders with some of the bigger innovators and tap into new clientele.

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

“We have seen the benefits of having a physical presence in Harvard Square, and it has served us really well,” said Anders Lindstrom, director of marketing at Sygnature, in a statement. “The opportunity to move closer to the Kendall Square centre of the biotech cluster was one we could not pass up. One of our key strengths is our collaborative approach to drug discovery, and a physical presence as close as possible to customers is important, so this crucible of drug discovery is the perfect place for us.”

RELATED: Sygnature Discovery debuts expansion plans for its U.K. campus

Sygnature’s senior vice president of business development, Paul Clewlow, added: “We believe the services and expertise we have within Sygnature is perfectly tuned to providing the resource and expertise our customers need to take forward their innovative drug discovery programmes. A huge amount of exciting drug discovery is going on in the Boston–Cambridge area: not just biotechs, but big pharma is congregating there now as well. It is a great hub for us from where to better serve our North American customer base.”

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.